Related Experiment Videos
Matrix metalloproteinase-9 in cerebral aneurysms
1Department of Neurological Surgery, Columbia University, College of Physicians and Surgeons, New York, New York, USA.
Neurosurgery
|October 6, 1997
Summary
Matrix metalloproteinase-9 (MMP-9) is elevated in cerebral aneurysm walls, suggesting a local role in arterial disruption. Systemic MMP-9 levels and plasma activity do not differ, limiting screening utility.
Area of Science:
- Vascular Biology
- Biochemistry
- Neurology
Background:
- Cerebral aneurysms involve arterial wall changes, but their cause is unclear.
- Matrix metalloproteinase-9 (MMP-9) is implicated in tissue degradation.
Purpose of the Study:
- To investigate the role of MMP-9 in cerebral aneurysm pathogenesis.
- Compare MMP-9 and its inhibitor (TIMP) levels in aneurysm walls versus normal arteries.
- Assess plasma MMP-9 activity in aneurysm patients.
Main Methods:
- Excised aneurysm walls and superficial temporal artery (STA) segments.
- Analyzed MMP-9 and TIMP tissue levels using Western blot.
- Measured plasma MMP-9 activity via zymography.
Main Results:
- MMP-9 and TIMP levels were significantly higher in aneurysm walls compared to extracranial and intracranial arteries.
- No differences in MMP-9 levels were found in STAs between aneurysm patients and controls.
- Plasma MMP-9 activity showed no significant difference between groups.
Conclusions:
- Elevated local MMP-9 in aneurysm walls, not systemic levels, likely contributes to arterial disruption.
- Increased MMP-9 is independent of TIMP down-regulation.
- Plasma MMP-9 activity is not a viable biomarker for presymptomatic cerebral aneurysms.